Antihypertensive treatment is associated with improved left ventricular geometry: The Rotterdam study

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 10, 2004, Pages 703-709

  Bleumink, Gysèle S ^a,b   Deinum, Jaap ^a   Mosterd, Arend ^c   Witteman, Jaqueline C M ^a   Hofman, Albert ^a   Stricker, Bruno H Ch ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Drug Safety Unit   (Netherlands)

^c EEMLAND HOSPITAL   (Netherlands)

Author keywords

Antihypertensive agents; Echocardiography; Elderly; Hypertrophy; Population

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG MECHANISM; DRUG RESPONSE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GEOMETRY; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK REDUCTION; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; PROSPECTIVE STUDIES;

EID: 5744251078     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.947     Document Type: Article

References (35)

1. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
2. Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35: 580-586.
3. Wachtell K, Bella JN, Liebson PR, et al. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE Study. Hypertension 2000; 35: 6-12.
4. Gardin JM, Siscovick D, Anton-Culver H, et al. Sex, age, and disease affect echocardiographic left ventricular mass and systolic function in the free living elderly: the Cardiovascular Health Study. Circulation 1995; 91: 1739-1748.
5. Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation 2000; 101: 2271-2276.
6. Mansoor GA, Massie BM. Left ventricular hypertrophy: a potent cardiovascular risk factor and its relationship to office and ambulatory blood pressure. Blood Press Monit 1999; 4: S19-S22.
7. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114 345-352.
8. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48-54.
9. Muiesan ML, Salvetti M, Rizzoni D, et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13: 1091-1095.
10. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998; 13: 564-569.
11. Sheridan DJ. Regression of left ventricular hypertrophy: do antihypertensive classes differ? J Hypertens 2000; 18: S21-S27.
12. Andren B, Lind L, Lithell H. The influence of different antihypertensive drugs on left ventricular hypertrophy in a population sample of elderly men. J Hum Hypertens 1999; 13: 499-504.
13. Hamada M, Ohtani T, Suzuki M, et al. Is left ventricular systolic dysfunction in hypertensive patients with heart failure normalized by long-term antihypertensive therapy? J Cardiol 1993; 23: 165-175.
14. Hofman A, Grobbee DE, de Jong PTVM, van de Ouwehand FA. Determinants of disease and disability in the elderly: the Rotterdam Study. Eur J Epidemiol 1991; 7: 403-422.
15. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J 1999; 20: 447-455.
16. Van Rossum CTM, van de Mheen H, Witteman JCM, et al. Prevalence, treatment, and control of hypertension by sociodemographic factors among the Dutch elderly. Hypertension 2000; 35: 814-821.
17. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
18. Agabati-Rosei E, Zulli R, Muiesan ML, et al. Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients. Blood Press 1998; 7: 160-169.
19. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
20. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 15(57): 450-458.
21. Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35: 580-586.
22. Reichek N, Devereux RB. Reliable estimation of peak left ventricular systolic pressure by M-mode echocardiographic-determined end-diastolic relative wall thickness: identification of severe valvular aortic stenosis in adult patients. Am Heart J 1982; 103: 202-209.
23. Pelkonen R, Pyorala K, Kangas T. (Diagnostic criteria and classification of diabetes; new recommendations of the WHO committee) Diabeteksen diagnostiset kriteerit ja luokitus. Duodecim 1981; 97: 920-924.
24. Fagerberg B, Wikstrand J, Berglund G, et al. Withdrawal of antihypertensive drug treatment: time-course for redevelopment of hypertension and effects upon left ventricular mass. J Hypertens 1992; 10: 587-593.
25. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ 1997; 315 1151-1154.
26. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91: 698-706.
27. Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE Study. J Hypertens 2000; 18: 1465-1475.
28. Gottdiener JS, Reda DJ, Massie BM, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation 1997; 95: 2007-2014.
29. Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD Echocardiographic Substudy. Circulation 1995; 91: 2573-2581.
30. De Rosa ML, Maddaluno G, Lionetti F, et al. Effects of enalapril and isradipine alone and in combination on blood pressure, renal function and echocardiographic parameters in mild hypertension. Int J Cardiol 2000; 74: 77-84.
31. Tanser PH. Hypertrophy to failure. J Hum Hypertens 1994; 8: S17-S20.
32. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000; 102 470-479.
33. Drayer JI, Gardin JM, Weber MA, Aronow WS. Changes in ventricular septal thickness during diuretic therapy. Clin Pharmacol Ther 1982; 32: 283-288.
34. Michalewicz L, Messerli FH. Cardiac effects of calcium antagonists in systemic hypertension. Am J Cardiol 1997; 79: 39-46.
35. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001; 104: 1248-1254.